Tumult in the bacterial community that occupies your gut—known as your microbiome—doesn’t just cause indigestion. For people recovering from a stroke, it may influence how they get better.
A recent study by Allison Brichacek and Candice Brown, researchers in the West Virginia University School of Medicine, suggests that stroke patients’ microbiomes—and even the structure of their guts—may still be out of kilter a month after the stroke has passed.
“We’re interested in the gut-brain axis—how the gut influences the brain and vice versa,” said Brichacek, a doctoral student in the immunology and microbial pathogenesis graduate program. She presented her findings at the International Stroke Conference in February.
Previous studies indicated the immediate effects a stroke can have on someone’s microbiome, but they didn’t explore whether these effects lingered. To find out, Brichacek, Brown and their colleagues—including Sophia Kenney, an undergraduate majoring in immunology and medical microbiology, and Stan Benkovic, a researcher in Brown’s lab—induced a stroke in animal models. Other models—the control group—didn’t have a stroke. The researchers compared the two groups’ microbiomes three days, 14 days and 28 days post-stroke. They also scrutinized their intestines for microscopic disparities.
Bacterial friend or foe?
One of the researchers’ discoveries was that a certain family of bacteria— Bifidobacteriaceae—was less prominent in post-stroke models than in healthy ones both 14 and 28 days out. If the name of the family sounds familiar, that’s probably because Bifidobacterium—a genus within theBifidobacteriaceae family—is a common ingredient in yogurt and probiotics. These bacteria are known for supporting digestive health and may be associated with better outcomes in stroke patients.
That may sound like bad news for people who have had a stroke, but the loss of Bifidobacteriaceae bacteria isn’t the only long-term change their microbiomes undergo. Another family associated with worse outcomes—Helicobacteraceae—was also more common in post-stroke models 28 days out. The practical implications of these microbiotic shifts are still unknown.
The team also found that the ratio of one type of bacteria—Firmicutes—to another—Bacteriodetes—was higher in post-stroke models. After 14 days, the ratio in the experimental group was almost six times higher than in the control group. After 28 days, the experimental group’s ratio had fallen, but it was still more than triple that of the control group. Having a high Firmicutes-to-Bacteriodetes ratio can be concerning because of its link to obesity, diabetes and inflammation.
The gut-brain axis seems to distribute a stroke’s effects in another way, too. The research team discovered that a stroke can cause intestinal abnormalities. Under magnification, the intestinal tissues of healthy models resembled an orderly colony of coral. The branches of “coral” were actually villi—tiny projections that increase the surface area of the intestinal wall and multiply the amount of nutrients it can absorb.
But in post-stroke models, the intestinal tissue looked scrambled, even a month after researchers triggered the stroke. “There’s disorganization here,” Brichacek said. “There’s also less space between the villi to allow nutrients to move around.” Poor circulation of nutrients can lead to compromised stroke recovery.
Treating the brain by treating the gut
What does all of this mean for stroke recovery? “Big picture: seeing a persistent, chronic change 28 days after stroke that is associated with this increase in some of the negative bacteria means that this could have negative effects on brain function and behavior. Ultimately, this could slow or prevent post-stroke recovery,” said Brown, an assistant professor in Department of Neuroscience and faculty member in the Rockefeller Neuroscience Institute.
Her and Brichacek’s findings may point to new therapeutic options for stroke. “If it ends up being that the gut has an influence on the repair of the brain, maybe our stroke treatments shouldn’t just be focused on what we can do for the brain. Maybe we need to think about what can we do for the gut,” Brichacek said.
For example, some bacteria in the gut produce short-chain fatty acids that affect brain function. “Some of these short-chain fatty acids are good, and some are bad,” said Brown. “If the bacteria that produce some of the bad short-chain fatty acids are proliferating, that could have a negative outcome for brain function.” Could nudging a stroke patient’s microbiome in a healthier direction—using probiotic supplements or prebiotic foods, for instance—help prevent emotional or cognitive decline?
Likewise, might it be possible to lower a stroke patient’s Firmicutes-to-Bacteriodetes ratio and promote weight loss, decrease diabetes risk and make subsequent strokes less likely?
The researchers’ next step is to study intestinal changes in more depth. Just as the blood-brain barrier isolates the brain from the blood circulating elsewhere in the body, a barrier seals off the intestine from its surroundings. Brown and Brichacek want to know how a breach in the intestinal barrier could affect the central nervous system. Protecting this barrier is critical for the function of the enteric nervous system—a part of the peripheral nervous system that includes the gut and often is called our “second brain” or “little brain.”
“People don’t appreciate the gut. It controls much more than digestion,” Brown said. “Our results suggest that stroke targets both brains—the brain in our head and the brain in our gut.”
The Latest on: Microbiome
via Google News
The Latest on: Microbiome
- Parasitic infections are closely linked to the microbiomeon June 24, 2020 at 10:36 am
"We found that we could look at someone's microbiome and use it to predict whether someone had a gastrointestinal parasite infection," say the researchers.
- Research shows tongue microbiome could help diagnose heart failureon June 23, 2020 at 8:06 am
Microorganisms on the tongue could help diagnose heart failure, according to research presented today on HFA Discoveries, a scientific platform of the European Society of Cardiology (ESC).1 ...
- Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting IIon June 22, 2020 at 6:53 pm
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.
- Effects of a high fat diet on gut microbiome dysbiosis in a mouse model of Gulf War Illnesson June 22, 2020 at 12:20 pm
Gulf War Illness (GWI) is a chronic health condition that appeared in Veterans after returning home from the Gulf War. The primary symptoms linked to deployment are posttraumatic stress disorder, mood ...
- Microbial transmission in animal social networks and the social microbiomeon June 22, 2020 at 8:09 am
This Perspective discusses the microbial metacommunity of animal social groups, and the social and environmental forces that shape it at different levels, from individuals to species.
- Gut reaction: How the gut microbiome may influence the severity of COVID-19on June 22, 2020 at 7:00 am
The risk of severe COVID-19 infection is more common in those with high blood pressure, diabetes and obesity, conditions that are all associated with changes to the composition of the gut ...
- Patient genetics associated with wound microbiome composition and healingon June 21, 2020 at 5:01 pm
Caleb Phillips, an assistant professor at Texas Tech University and director of the Phillips Laboratory in the Department of Biological Sciences, and doctoral student Craig Tipton led the study, ...
- In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placeboon June 19, 2020 at 2:33 pm
Mark Smith was at MIT doing basic research into the microbiome. Now, as CEO of Finch Therapeutics Group, Smith has hard data to back up his ...
- Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infectionon June 19, 2020 at 4:27 am
Finch Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. Diff ...
- Finch touts positive results for its microbiome pill for C. diff infectionson June 19, 2020 at 4:12 am
Three-quarters of the people who got Finch Therapeutics’ microbe-based pill for C. difficile infections appeared to be cured, the company announced Friday.
via Bing News